Skip to content

Study · Ex vivo tissue · 2000

7 results

Growth hormone secretagogue binding sites in peripheral human tissues.

Papotti M, Ghè C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, Muccioli G

The Journal of clinical endocrinology and metabolism1 Oct 2000Cited by 298 (Europe PMC)

PMID11061542 (opens in a new tab)DOI10.1210/jcem.85.10.6846 (opens in a new tab)PepBankPUB-11061542
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In human endocrine tissues, hexarelin completely displaced the radioligand and was more potent than MK 0677 and human ghrelin.

    In plain wordsIn lab tests on human endocrine tissue, hexarelin displaced a labelled ligand from binding sites more strongly than MK 0677 or ghrelin.

    Peptide
    Hexarelin
    Outcome
    Not applicableDisplacement of radioligand in endocrine tissues
    Study

    humann: not reported in source

    human tissues, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin, MK 0677, and human ghrelin completely displaced the radioligand from binding sites of endocrine tissues, but MK 0677 and ghrelin were less potent than hexarelin.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.
  2. 02LabEx vivo tissueActivity measurement

    In human nonendocrine tissues, hexarelin displaced the radioligand, whereas MK 0677 and ghrelin were inactive.

    In plain wordsIn lab tests on human non-hormone tissue, hexarelin displaced a labelled ligand from binding sites, but MK 0677 and ghrelin did not.

    Peptide
    Hexarelin
    Outcome
    Not applicableDisplacement of radioligand in nonendocrine tissues
    Study

    humann: not reported in source

    human tissues, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In nonendocrine tissues, both MK 0677 and ghrelin were inactive in displacement of [125I]Tyr-Ala-hexarelin, whereas hexarelin was as active as a displacing agent in endocrine tissues.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.
  3. 03LabEx vivo tissueActivity measurement

    In human endocrine tissues, MK 0677 completely displaced labeled Tyr-Ala-hexarelin from binding sites.

    In plain wordsIn lab tests, MK 0677 fully displaced the labeled ligand from human endocrine tissue binding sites.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseEndocrine radioligand displacement
    Study

    humann: not reported in source

    endocrine tissue binding sites
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin, MK 0677, and human ghrelin completely displaced the radioligand from binding sites of endocrine tissues, but MK 0677 and ghrelin were less potent than hexarelin.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.
  4. 04LabEx vivo tissueActivity measurement

    In human endocrine tissues, MK 0677 was less potent than hexarelin at radioligand displacement.

    In plain wordsIn lab tests, MK 0677 displaced the labeled ligand less potently than hexarelin in human endocrine tissues.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseEndocrine displacement potency
    Study

    humann: not reported in source

    endocrine tissue binding sites
    Comparator
    Hexarelin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin, MK 0677, and human ghrelin completely displaced the radioligand from binding sites of endocrine tissues, but MK 0677 and ghrelin were less potent than hexarelin.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.
  5. 05LabEx vivo tissueActivity measurement

    In human nonendocrine tissues, MK 0677 was inactive at displacing labeled Tyr-Ala-hexarelin.

    In plain wordsIn lab tests, MK 0677 did not displace the labeled ligand from human nonendocrine tissue binding sites.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeNonendocrine radioligand displacement
    Study

    humann: not reported in source

    nonendocrine tissue binding sites
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In nonendocrine tissues, both MK 0677 and ghrelin were inactive in displacement of [125I]Tyr-Ala-hexarelin, whereas hexarelin was as active as a displacing agent in endocrine tissues.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 06LabNot a test of Hexarelin aloneEx vivo tissueActivity measurement

    In human tissues, a radioreceptor assay with a labelled hexarelin analogue found GHS receptors mainly in the myocardium, and also in adrenal, gonads, arteries, lung and other tissues.

    In plain wordsIn lab tests on human tissue, a labelled hexarelin analogue bound mostly in heart muscle, and also in many other tissues.

    Peptide
    Hexarelin
    Outcome
    Not applicableTissue distribution of GHS receptor binding of a labelled hexarelin analogue
    Study

    humann: not reported in source

    human tissues, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    GHS receptors were detected mainly in the myocardium, but they were also present (in order of decreasing binding activity) in adrenal, gonads, arteries, lung, liver, skeletal muscle, kidney, pituitary, thyroid, adipose tissue, veins, uterus, skin, and lymphnode.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 07LabNot a test of Hexarelin aloneEx vivo tissueActivity measurement

    In human tissues, a radioreceptor assay with a labelled hexarelin analogue found negligible binding in parathyroid, pancreas, placenta, mammary gland, prostate, salivary gland, stomach, colon and spleen.

    In plain wordsIn lab tests on human tissue, a labelled hexarelin analogue showed almost no binding in several tissues, including pancreas and stomach.

    Peptide
    Hexarelin
    Outcome
    Not applicableNegligible binding of a labelled hexarelin analogue in some tissues
    Study

    humann: not reported in source

    human tissues, radioreceptor assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In contrast, negligible binding was found in parathyroid, pancreas, placenta, mammary gland, prostate, salivary gland, stomach, colon, and spleen.
    1 context sentence
    Summary · context
    Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.